ABSTRACT
Background: Coronavirus disease 2019 (COVID-19] has become a global pandemic. Preventive policy during this outbreak possibly leads to a negative influence on the highly time-sensitive diseases such as acute ischemic stroke (AIS]. Objective(s): The present study was to determine the impact of the pandemic on rate of recombinant tissue plasminogen activator (rtPA] administration for AIS in Thailand. Material(s) and Method(s): A cross-sectional descriptive study. The magnitude of COVID-19 pandemic in each province of Thailand was reviewed from the website of the Ministry of Public Health. The number of patients with AIS who received rtPA was taken from the National Health Security Office, from 1st October 2019 to 21st August 2021. The authors demonstrate the correlation between the pandemic severity and the rate of rtPA administration for patients with AIS. Result(s): During the COVID-19 pandemic, there were 37 provinces (48%] in year 2020 and SO provinces (64.9%] in year 2021 had a reduction in rate of rtPA administration, 40 provinces (51.9%] in year 2020 and 27 provinces (35%] in year 2021 had increase in rate of rtPA administration. Over a period of two years, 25 provinces (32.5%] had only decreased rate (mean=1.12% and 1.63% in year 2020 and 2021 respectively], 15 provinces (19.5%) had only increased rate (mean=1.71% and 1.17% in year 2020 and 2021 respectively], and 37 provinces (48%] had diverse in rate of rtPA administration among both years. Conclusion(s): The present study demonstrated that the COVID-19 pandemic does not cause a significant impact on the rate of rtPA administration for AIS in Thailand.Copyright © 2023 Journal of the Medical Association of Thailand.
ABSTRACT
Background: Efficacy of telemedicine for stroke was first established by the Stroke Team Remote Evaluation Using a Digital Observation Camera (STRokE DOC) trials in California and Arizona. Following these randomized controlled trials, the Stroke Telemedicine for Arizona Rural Residents (STARR) network was the first telestroke network to be established in Arizona. It consisted of a 7 spoke 1 hub telestroke system, and it was designed to serve rural, remote, or neurologically underserved communities. Objective: The objective of STARR was to establish a multicenter state-wide telestroke research network to determine the feasibility of prospective collection, recording, and regularly analysis of telestroke patient consultations and care data for the purposes of establishing quality measures, improvement, and benchmarking against other national and international telestroke programs. Methods: The STARR trial was open to enrollment for 29 months from 2008 to 2011. Mayo Clinic Hospital, Phoenix, Arizona served as the hub primary stroke center and its vascular neurologists provided emergency telestroke consultations to seven participating rural, remote, or underserved spoke community hospitals in Arizona. Eligibility criteria for activation of a telestroke alert and study enrollment were established. Consecutive patients exhibiting symptoms and signs of acute stroke within a 12 h window were enrolled, assessed, and treated by telemedicine. The state government sponsor, Arizona Department of Health Services' research grant covered the cost of acquisition, maintenance, and service of the selected telemedicine equipment as well as the professional telestroke services provided. The study deployed multiple telemedicine video cart systems, picture archive and communications systems software, and call management solutions. The STARR protocol was reviewed and approved by Mayo Clinic IRB, which served as the central IRB of record for all the participating hospitals, and the trial was registered at ClinicalTrials.gov. Results: The telestroke hotline was activated 537 times, and ultimately 443 subjects met criteria and consented to participate. The STARR successfully established a multicenter state-wide telestroke research network. The STARR developed a feasible and pragmatic approach to the prospective collection, storage, and analysis of telestroke patient consultations and care data for the purposes of establishing quality measures and tracking improvement. STARR benchmarked well against other national and international telestroke programs. STARR helped set the foundation for multiple regional and state telestroke networks and ultimately evolved into a national telestroke network. Conclusions: Multiple small and rurally located community hospitals and health systems can successfully collaborate with a more centrally located larger hospital center through telemedicine technologies to develop a coordinated approach to the assessment, diagnosis, and emergency treatment of patients manifesting symptoms and signs of an acute stroke syndrome. This model may serve well the needs of patients presenting with other time-sensitive medical emergencies.Clinical Trial Registration number: NCT00829361.
ABSTRACT
Coronavirus disease 2019 (COVID-19) predominantly manifests with signs of respiratory system injury;however, multi-systemic manifestations may occur. Renal pathology develops in up to 80% of patients with COVID-19. The aim of the study was to describe the case of isolated massive polyuria of unknown etiology in the patient with severe COVID-19-related pneumonia complicated by pulmonary embolism (PE). A 54-year-old male with bilateral pneumonia, related to COVID-19, developed PE. The next day after successful thrombolysis with alteplase (90 mg) the diuresis of the patient began to increase and fluctuated between 5000 mL and 8000 mL. The diuresis returned to normal ranges two weeks after PE episode. The rise of the diuresis was not accompanied by electrolyte disorders and elevation of serum creatinine. Changes in the urine tests were minimal, only once the urine protein was detected (0.25 g/L). The highest urine excretion was observed in evening hours (16.00-24.00). Chest CT on the day 14 after the patient's admission revealed 90% of lung tissue injury, cranial CT showed no brain abnormalities, including hypothalamus and pituitary gland. The patient's condition met neither diagnostic criteria of acute kidney injury, nor acute interstitial nephritis, nor pituitary gland damage. The course of the polyuria in the presented case was benign (self-limiting, no blood electrolyte abnormalities, compensated by oral rehydration only). Polyuria in patients with COVID-19 may not be a life-threatening condition that does not require active treatment.Copyright © 2021 EDIZIONI MINERVA MEDICA.
ABSTRACT
Objective: To describe ischemic stroke due to floating thrombus of ascending aorta occurring as acute and subacute complication of SARS-CoV-2 infection. Material(s) and Method(s): consecutive identification in clinical practice of ischemic strokes secondary to aortic arch thrombosis and history of acute or recent Covid-19 infection. Result(s): two patients had ischemic stroke with evidence of aortic arch thrombosis. The first case had concomitant acute Covid-19 infection, the second had recent Covid-19 infection. Both patients underwent intravenous thrombolysis, and subsequent anticoagulation. One patient died due to cerebral hemorrhage. Discussion and Conclusion(s): aortic arch thrombosis can be an incidental finding in acute ischemic stroke in patients with concomitant and recent COVID-19 disease. However, the infection may lead to thrombosis in non-atherosclerotic vessels and to cerebral embolism. Our findings support active radiological search for aortic thrombosis during acute stroke in patients with acute or recent COVID-19 disease.Copyright © 2022
ABSTRACT
Background Effusive constrictive pericarditis can initially mimic heart failure and ultimately result in cardiogenic shock. Case Patient is a 57-year-old female with history of recent massive pulmonary embolism status post systemic alteplase, chronic diastolic heart failure, and history of COVID-19 infection presenting with increasing dyspnea on exertion and weakness despite compliance to outpatient diuretics. Patient was noted to be hypotensive, and fluid overloaded on exam. Decision-making Due to concern for constriction right heart catheterization (RHC) was completed and showed cardiac index of 1.1 with elevated filling pressures, discordant variation of right ventricle (RV) and left ventricle (LV) pressure tracings, diastolic equalization of pressure, and dip and plateau pattern of RV and LV diastolic tracing suggestive of constrictive physiology. Transesophageal echocardiogram showed no pericardial effusion with increased echo-density of the pericardium. Cardiac MRI showed mild diffuse thickening and subtle enhancement of the pericardium with septal bounce and no significant pericardial effusion consistent with constrictive pericarditis. Due to persistent hypotension requiring milrinone infusion, the patient underwent pericardiectomy with improvement of hemodynamics and symptoms. Conclusion Effusive constrictive pericarditis can mimic heart failure and should be ruled out in those with evidence of low cardiac output to avoid cardiovascular morbidity and mortality. [Formula presented]Copyright © 2023 American College of Cardiology Foundation
ABSTRACT
Objectives: There has been a significant increase in pulmonary embolism (PE) cases during the coronavirus disease of 2019 (COVID-19) pandemic. In this study, we aimed to compare the effects of COVID-19 positivity on morbidity and mortality in patients treated with a diagnosis of high-risk PE. Method(s): In this single-center and observational study, patients who were referred to our center with the diagnosis of PE between January 1, 2019 and 2021 were retrospectively evaluated. Patients with moderate- and low-risk PE according to the European Society of Cardiology PE guidelines, those who did not undergo computed tomography pulmonary angiography (CTPA) or the ones who did not accept treatment were excluded from the study. The patients included in the study were divided into two groups, as those with and without COVID-19, and compared in terms of demographic data, comorbidities, symptoms, thromboembolism in vessels other than the pulmonary artery, laboratory parameters, treatments, and prognosis. Result(s): A total of 384 PE cases were identified during the study period. Among them, 322 cases that were in the intermediate or low-risk category, 21 cases who did not undergo CTPA, and one case who did not accept thrombolytic therapy were excluded from the study. A total of 40 cases were included in the study. The groups with and without COVID-19 consisted of 23 and 17 patients, respectively. In the group of patients with COVID-19, inflammatory markers were higher, Wells score was lower, and thromboembolism was seen in vessels other than the pulmonary artery. The two groups were similar in terms of other laboratory parameters, demographic data, comorbidities, symptoms, treatment, and prognosis. Conclusion(s): While the involvement of COVID-19 in PE etiology does not change mortality, it may cause more thrombosis development in both venous and arterial systems outside the pulmonary area by significantly increasing inflammation. However, the lower Wells scores in COVID-19 PE cases in our study indicate that new clinical assessment tools are needed to detect PE risk in COVID-19 patients.©Copyright 2022 by The Cardiovascular Thoracic Anaesthesia and Intensive Care.
ABSTRACT
BACKGROUND: Fibrinolysisis is essential for vascular blood flow maintenance and is triggered by endothelial and platelet release of tissue plasminogen activator (t-PA). In certain critical conditions, e.g. sepsis, acute respiratory failure (ARF) and trauma, the fibrinolytic response is reduced and may lead to widespread thrombosis and multi-organ failure. The mechanisms underpinning fibrinolysis resistance include reduced t-PA expression and/or release, reduced t-PA and/or plasmin effect due to elevated inhibitor levels, increased consumption and/or clearance. This study in critically ill patients with fibrinolysis resistance aimed to evaluate the ability of t-PA and plasminogen supplementation to restore fibrinolysis with assessment using point-of-care ClotPro viscoelastic testing (VET). METHODS: In prospective, observational studies, whole-blood ClotPro VET evaluation was carried out in 105 critically ill patients. In 32 of 58 patients identified as fibrinolysis-resistant (clot lysis time > 300 s on the TPA-test: tissue factor activated coagulation with t-PA accelerated fibrinolysis), consecutive experimental whole-blood VET was carried out with repeat TPA-tests spiked with additional t-PA and/or plasminogen and the effect on lysis time determined. In an interventional study in a patient with ARF and fibrinolysis resistance, the impact of a 24 h intravenous low-dose alteplase infusion on coagulation and fibrinolysis was prospectively monitored using standard ClotPro VET. RESULTS: Distinct response groups emerged in the ex vivo experimental VET, with increased fibrinolysis observed following supplementation with (i) t-PA only or (ii) plasminogen and t-PA. A baseline TPA-test lysis time of > 1000 s was associated with the latter group. In the interventional study, a gradual reduction (25%) in serial TPA-test lysis times was observed during the 24 h low-dose alteplase infusion. CONCLUSIONS: ClotPro viscoelastic testing, the associated TPA-test and the novel experimental assays may be utilised to (i) investigate the potential mechanisms of fibrinolysis resistance, (ii) guide corrective treatment and (iii) monitor in real-time the treatment effect. Such a precision medicine and personalised treatment approach to the management of fibrinolysis resistance has the potential to increase treatment benefit, while minimising adverse events in critically ill patients. TRIAL REGISTRATION: VETtiPAT-ARF, a clinical trial evaluating ClotPro-guided t-PA (alteplase) administration in fibrinolysis-resistant patients with ARF, is ongoing (ClinicalTrials.gov NCT05540834 ; retrospectively registered September 15th 2022).
Subject(s)
Fibrinolysis , Tissue Plasminogen Activator , Humans , Tissue Plasminogen Activator/pharmacology , Tissue Plasminogen Activator/therapeutic use , Fibrin Clot Lysis Time , Point-of-Care Systems , Prospective Studies , Feasibility Studies , Critical Illness/therapy , Plasminogen/pharmacologyABSTRACT
Pulmonary embolism has a high frequency in COVID-19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID-19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis.
ABSTRACT
Coronavirus disease 2019 (COVID-19) has been associated with respiratory failure and high mortality. Hypercoagulability and thromboembolic complications have been found in a high percentage of patients amongst which, pulmonary embolism (PE) is the most common. Currently, there are no guidelines on using thrombolysis therapy in COVID-19 patients who developed PE. We present five survivors aged 30-75 years old with confirmed COVID-19. All cases were proven by computed tomography pulmonary angiogram (CTPA) to have PE treated with low-dose recombinant tissue plasminogen activator (rtPA). PE should be suspected in all COVID-19 patients with rapid worsening of dyspnea, desaturation, unexplained shock, and increased level of D-dimer and fibrinogen. In our cases, PE developed despite preventative anticoagulation regimens with low molecular weight heparin. After thrombolytic therapy, all patients showed improvement in partial-arterial-oxygen-pressure to inspired oxygen-fraction ratio (arterial partial pressure of oxygen/inspired oxygen fraction ratio). D-dimer showed elevation after thrombolytic therapy and decreased in the following days. Fibrinogen levels decreased following thrombolytic therapy. Current anticoagulation regimens seem insufficient to halt the course of thrombosis, and thrombolytic therapy may be beneficial for patients with severe COVID-19 and PE. Systemic thrombolysis therapy is a double-edged sword, and clinicians must balance between benefit and risk of bleeding.
Subject(s)
Humans , Female , Adult , Pulmonary Embolism , Thrombolytic Therapy , Tissue Plasminogen Activator , SARS-CoV-2 , COVID-19Subject(s)
Humans , Female , Adult , Pulmonary Embolism , Thrombolytic Therapy , Tissue Plasminogen Activator , SARS-CoV-2 , COVID-19ABSTRACT
This study was conducted with the primary aim to distinguish patients with a true stroke versus a stroke mimic based on clinical features and imaging. We conducted a retrospective case-control study on 116 adult patients who received alteplase (tPA) to treat acute stroke at our hospital. We further analyzed 79 patients with a normal computed tomography angiography (CTA). Based on their magnetic resonance imaging (MRI) of the brain, they were divided into cases (stroke mimics) and controls (true strokes). Data were collected retrospectively by reviewing individual medical charts on the electronic medical record (EMR), including age, gender, history of stroke, seizure, hypertension, diabetes, atrial fibrillation, hyperlipidemia, presenting NIH Stroke Scale/Score, hemorrhagic conversion, history of migraine, history of depression, sidedness of symptoms and aphasia. Data were categorized to separate those who were later diagnosed to be stroke mimics by being-postictal, encephalopathic, in acute migraine, suffered post-stroke recrudescence (PSR) due to metabolic insult, or had conversion disorder when symptoms could not be attributed to any medical condition or mental illness. Of the 79 study subjects, 48 (60%) were stroke mimics. The mean age of the cohort was 68.67 years, and 46.8% of the study subjects were females. Based on the multivariate logistic regression analysis, factors associated with being a stroke mimic were older age, history of migraine, and a history of prior stroke. In conclusion, increased attention to history and clinical examination as the first step can aid in the proper diagnosis of strokes versus stroke mimics. Identifying stroke mimics early could help expedite hospital workup and prevent inadvertent investigations, reducing hospital occupancy during the ongoing COVID-19 pandemic. We could potentially avoid the administration of tPA to such patients, reducing both the cost and adverse effects of it. Every stroke can cause neurological deficits, but every deficit need not be a stroke.
ABSTRACT
SESSION TITLE: Bedside Ultrasound Cases: Beyond Our Sight SESSION TYPE: Case Reports PRESENTED ON: 10/19/2022 09:15 am - 10:15 am INTRODUCTION: A thrombus-in-transit (TT), although rare, occurring in approximately 4-18% of pulmonary embolism (PE) cases, carries a high risk of mortality. One study commenting on 80-100% without treatment;therefore, TT should be considered a medical emergency and treated immediately. CASE PRESENTATION: A 64 years old female patient with history of Hypertension and morbid obesity presented to the Emergency department complaining of shortness of breath for 2 weeks with rapid worsening of symptoms and new chest pain in the previous 2 days. Patient blood pressure was 110/70, heart rate 160 irregularly irregular saturating 91% on room air, respiratory rate of 25. Patient tested positive for SARS-CoV-2, and her basic blood work showed elevated BNP and troponin with significant elevation of D-Dimer. The patient never smoked, had no recent travel and not taking OCPs. Bed side point of care echocardiogram showed large right atrial thrombus floating between the right atrium and right ventricle. Subsequent lower extremity ultrasound showed extensive left femoral thrombosis and pulmonary CT Angiogram showed a PE. The treatment options were discussed with the patient including giving full or half dose thrombolytics, or just anticoagulation with heparin. The patient opted for anticoagulation alone. Unfortunately, the patient had a cardiac arrest few hours later. Thrombolytics were given during CPR but the patient passed away. DISCUSSION: TT refers to free-floating right heart thrombi that travel from a venous source in the lower extremities to the pulmonary arteries. Although rare, the presence of a right heart thrombi in the setting of PE predicts a worse prognosis with a high mortality rate and thus, should be treated as a medical emergency. The diagnostic test of choice for TT is an echocardiogram, which shows an elongated right-sided mass illustrating high and chaotic motility with changing shape that continuously prolapses in and out of the right ventricle. Management of TT is still not well established. Options include anticoagulation with heparin, thrombolysis, or surgical removal. A particular study done by Greco et al. in 1999 used recombinant tissue plasminogen activator (rt-PA) with continuous echocardiogram monitoring, that revealed complete lysis of heart clots in all 7 patients within 24 hours. It also showed no changes in symptoms and ultimately showed improvement in blood pressure and heart rate. CONCLUSIONS: Available treatment options include anticoagulation alone, thrombolysis, or surgical embolectomy. Although anticoagulation can prevent clot propagation, it carries a mortality rate of up to 29%, comparable to surgical intervention. Surgical embolectomies could be an alternative option if contraindications to thrombolytics exist. Ultimately, no significant difference was found among the treatment options, suggesting the need for further research and clinical trials. Reference #1: Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–73. Reference #2: Cameron, James, et al. "Right Heart Thrombus: Recognition, Diagnosis and Management.” Journal of the American College of Cardiology, vol. 5, no. 5, 1985, pp. 1239–1243., https://doi.org/10.1016/s0735-1097(85)80031-0. Reference #3: Greco, Francesco, et al. "Successful Treatment of Right Heart Thromboemboli with IV Recombinant Tissue-Type Plasminogen Activator during Continuous Echocardiographic Monitoring.” Chest, vol. 116, no. 1, 1999, pp. 78–82., https://doi.org/10.1378/chest.116.1.78. DISCLOSURES: no disclosure on file for Ahmad alkhatatneh;No relevant relationships by Mohammad Alnabulsi No relevant relationships by Mohd Hazem Azzam No relevant relationships by Kelianne Comitalo
ABSTRACT
SESSION TITLE: Management of COVID-19-Induced Complications SESSION TYPE: Rapid Fire Case Reports PRESENTED ON: 10/19/2022 12:45 pm - 1:45 pm INTRODUCTION: We discuss a case of successful use of alteplase and dornase per MIST II protocol for the management of a loculated pleural effusion secondary to COVID-19 pneumonia. CASE PRESENTATION: 52 year old male was initially admitted for MRSA bacteremia and began appropriate antibiotic therapy. His chest radiograph on presentation was unremarkable. Seven days into his hospital course he tested positive for COVID-19 pneumonia, and developed increasing shortness of breath and escalating oxygen requirements. At this time he had a large loculated left sided pleural effusion on chest computed tomography. A pigtail catheter was placed with removal of 600ml of cloudy yellowish fluid. Follow-up CXR showed slight interval improvement, however a large loculated effusion remained. Pleural fluid studies was exudative, lymphocytic predominant (78%) with elevated pleural fluid lactate dehydrogenase of 786 U/L, pH 8.0, and glucose 97mg/dl. Additional pleural fluid workup was unremarkable, including negative cultures, AFB staining, and benign cytology. After other known causes of lymphocyte predominant pleural effusion were ruled out, and following review of the current medical literature, the conclusion was made that his effusion was most likely related to COVID-19. The decision was made to attempt lysis of the loculations with alteplase and dornase per MIST II protocol. This resulted in significant chest tube output (totaling 3480ml additional output over the ensuing days) as well as marked improvement in chest imaging. The protocol was continued for 3 days which the patient tolerated well overall. DISCUSSION: COVID-19 related pleural effusions occur with an incidence of about 7.3% of cases with an overall lag time of 11 days from symptom onset. Based on observational studies, these pleural effusions are unilateral in 66.8% of cases with a lymphocyte or neutrophilic predominance and significantly elevated pleural fluid to serum LDH ratio. The differential for exudative lymphocyte predominant pleural effusions with elevated LDH include malignancy, rheumatoid effusion, tuberculosis, and viral infections. The pleural studies workup was unremarkable for these conditions. The MIST-2 protocol was followed per the original study, with instillation of tPA 10mg via pigtail catheter which was clamped for 1 hour, opened to drain for 1 hour, then repeated with dornase 5mg. To the best of our knowledge, this is the first documented case of using MIST 2 protocol for a loculated pleural effusion related to COVID-19. CONCLUSIONS: COVID-19 related loculated pleural effusion is an infrequent occurrence that present as lymphocyte predominant exudative that can loculate with elevated lactate dehydrogenase. This is the first case of using alteplase and dornase for its management and we have demonstrated that it can be both a safe and effective method. Additional prospective studies are needed to further investigate this method. Reference #1: Chong WH, Saha BK, Conuel E, Chopra A. The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review. Heart Lung. 2021;50(4):481-490. doi:10.1016/j.hrtlng.2021.02.015 Reference #2: Ahmadinejad Z, Salahshour F, Dadras O, Rezaei H, SeyedAlinaghi S. Pleural Effusion as a Sign of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Case Report. Infect Disord Drug Targets. 2021;21(3):468-472. doi: 10.2174/1871526520666200609125045. PMID: 32516107. Reference #3: Rahman, N, et al. Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. N Engl J Med 2011;365:518-526. DOI: 10.1056/NEJMoa1012740 DISCLOSURES: No relevant relationships by Zachary Chandler No relevant relationships by James Cury No relevant relationships by Peter Staiano No relevant relationships by Daniel Weigle
ABSTRACT
Introduction: It is now well established that COVID-19 is linked to acute thrombosis. We present a case of an intubated and ventilated patient who received thrombolysis for acute limb ischemia. Shortly after intubation for respiratory failure secondary to COVID-19, a patient in their 50s developed a cold pulse less hand which was reviewed by vascular surgeons and radiologically diagnosed as acute arterial thrombosis resulting in an ischaemic hand. Objectives: Provide evidence for the use of systemic thrombolysis to treat thrombotic complications of COVID-19. Methods: Different treatment modalities were discussed within the multidisciplinary team. It was decided that the patient was unstable for transfer to theatre as he was in the proned position with severe respiratory failure. Therefore, systemic thrombolysis was administered to the patient twice over a period of 24 hours. Results: Following administration of Alteplase the patient went on to recover perfusion to the hand as well as making a remarkable respiratory improvement. This allowed for extubation within a matter of days. The patient survived to discharge without functional limitation of the hand. 6 months post discharge the patient is working full time in a manual capacity. Conclusions: We provide evidence that systemic thrombolysis can be considered as an option for acute limb ischemia in ventilated patients with COVID-19 for which conventional treatment options are not viable. With the knowledge that COVID-19 is a prothrombotic illness, it is possible that the thrombolysis of intercurrent pulmonary emboli contributed to respiratory recovery.
ABSTRACT
CASE: A 30-year-old previously healthy male presented with three weeks of progressively worsening pain, erythema, swelling in his left thigh, inability to bear weight and associated fatigue, fever, and dyspnea on exertion. Four weeks prior, he experienced 1 week of anosmia, fatigue, and “even worse” dyspnea on exertion with a resting heart rate in excess of 110 bpm and felt he most likely had had COVID. He self-treated for symptoms, rested, isolated and felt he had improved from COVID. The pain and swelling in the left leg increased over the prior three weeks and he sought care. On exam the left thigh was warm to touch, erythematous, and painful. Ultrasound imaging revealed left lower extremity deep venous thrombosis (DVT) extending from his upper thigh to lower leg. Abdominal/thoracic CT w/ contrast noted diffuse pulmonary emboli and May-Thurner Syndrome (MTS). Treatment was started with IV heparin followed by thrombolytic therapy with higher dose heparin and alteplase for 3 days. Shortly after this therapy was initiated, he developed significant hypoxia and was transferred to the ICU. He was stabilized and on the final day of thrombolytic therapy, a left common iliac vein stent was placed and he was discharged two days later on Apixaban and aspirin. IMPACT/DISCUSSION: May-Thurner syndrome (MTS), is an anatomical variant that may lead to venous outflow obstruction due to extrinsic compression by the iliac arterial system against bony structures in the iliocaval venous territory. Most common in the left leg, MTS is present in about 20% of the population and is more commonly found in women. It can result in venous hypertension and venous thromboembolisms (VTE). In serious and untreated cases, these VTEs can progress to pulmonary embolisms with resultant serious injury, hospitalization, and death. In this case, a recent COVID infection unearthed an MTS anomaly. The activated proinflammatory state induced by COVID is known to result in blood clots in hospitalized patients and appears to be related to a cytokine storm. This inflammatory state induces endothelial damage, microvascular thrombosis, and possibly pro-thrombotic antiphospholipid antibodies. In hospitalized patients with more severe disease VTE is commonly diagnosed, however the risk of COVID related coagulopathy in the outpatient setting is unknown. It appears that when blood clots do develop in outpatients, 1/5 have had a recent COVID infection which indicates an association between inflammation from infection contributes to VTE. In this case, the COVID complication helped to uncover a May-Thurner anomaly. CONCLUSION: - Delayed presentation can exacerbate COVID-related complications, even after acute symptoms have diminished - more should be done to educate patients on the dangers of post COVID thromboembolic disease. - Despite its prevalence in females, May-Thurners Syndrome should be in the differential for males with DVT.
ABSTRACT
Background: The world was witness to a pandemic never experienced by this generation. The call to arms was answered by each branch of medicine, each fighting separate wars. The war, we as neurologists faced was the “Battle for the Vessels”. Health care workers are a precious resource in Low-Middle-Income-Countries. Hence, exposure to a covidpositive patient for a “full hour” during thrombolysis, isn't warranted. Hence Tenecteplase use which fits the bill “ideally” and “literally” was analysed in this study against Alteplase in strokes with covid-positivity. We analyse the factors which affect their action and the role covid had, in each scenario. Methods: This is an ambi-spective observational study of 37 patients in an apex tertiary-care centre in India. Routine stroke variables were assessed including follow-up imaging, functional outcomes at 3 months. The results were also analysed with the thrombolysis data from covidnegative individuals too in the same period. Results: Among the covid-positive patients 62.16% patients received tenecteplase while 37.83% received alteplase. Although the baseline characteristics were similar, the time-metrics for thrombolysis were significantly favourable in the tenecteplase arm. The median-hospital stay was shorter in the tenecteplase group as was the in-hospital mortality. On follow-up at 3 months, the median mRS-score was significantly favourable in the tenecteplase group. Conclusions: Thrombolysis during the pandemic has been a challenge in many ways especially in resource limited settings. This study shows that there needs to be a conscious and judicial transition towards tenecteplase during the pandemic, where healthcare workers are a precious resource too.
ABSTRACT
Objective: To report a patient presenting with bulbar symptoms in the setting of COVID-19 infection leading to a new diagnosis of Myasthenia Gravis. Background: There have been many reports of neurological complications in patients with COVID-19 infection including Guillain Barre syndrome, Bell's palsy and transverse myelitis. There are limited case series describing the effects of COVID-19 in patients with known Myasthenia Gravis, but there have only been rare reports of new onset Myasthenia Gravis in the setting of COVID-19 infection. Design/Methods: Electronic medical records of the patient were reviewed. Results: 78 year old man presented to the hospital with new onset of dysphagia, dysarthria, bilateral ptosis and left facial droop. The patient was given intravenous alteplase for possible stroke. On admission the patient also tested positive for COVID-19. His symptoms persisted post-alteplase. On exam he was noted to have fatigable ptosis, weakness of brow elevation, eye closure, horizontal movements of the tongue and intermittent dysarthria, raising the concern for myasthenia gravis. A trial of Mestinon led to improved symptoms. Serum acetylcholine receptor antibodies were positive, confirming the Myasthenia Gravis diagnosis. He received 5 sessions of intravenous immunoglobulin (IVIG) due to persistent bulbar symptoms. He initially responded well to treatment but later decompensated with respiratory failure requiring intubation. He was then treated with plasmapheresis for 5 days with symptom improvement and was successfully extubated. Conclusions: Our patient with a new diagnosis of myasthenia gravis with simultaneous COVID-19 infection eventually progressed into myasthenic crisis. This case raises the possibility of myasthenia and/or myasthenic crisis being a neurological complication of COVID-19 infection. Mechanisms behind this have been postulated to include molecular mimicry, the inflammatory cascade of COVID-19 leading to immune dysregulation, or viral illness triggering previously asymptomatic patients. Awareness of new onset myasthenia associated with COVID-19 infection can lead to earlier diagnosis and treatment.
ABSTRACT
In February 2021, a PDTA on Pulmonary Embolism (PE) was approved in our hospital, including a chapter describing a protocol for the treatment with catheter thrombectomy (CT) of patients with high and intermediate risk PE. The protocol took into account the recommendations of the ESC 2019 guidelines on PE, and was produced to describe a path to improve the treatment of patients with PE It included: a) thrombectomy with aspiration in patients high-risk patients, with no haemodynamic improvement after administration of systemic thrombolytic therapy (TT) or with absolute contraindication to it;b) thrombectomy with loco-regional ultrasound-assisted thrombolysis (USAT) in patients at high-intermediate risk. 20 patients were treated from February 2020 to September 2021. 55% were men, with an average age of 73 ± 13 years;all patients met the criteria for inclusion in the protocol and signed a consensus document. 2 high-risk patients were treated with thromboaspiration: one patient for absolute contraindication to TT (recent spontaneous brain haemorrhage), the other one for a syncopal episode with head trauma. 18 patients (92%) at high intermediate risk were treated with USAT. For the 90% of patients were used 2 catheters;in 72% the administered dose of rt-PA was 24 mg. The mean value of NT- proBNP was 2,896 ng/l (normal m<93, f<144) There was only one major bleeding complication in the high-intermediate risk group (macrohematuria) during hospitalization. The mean RV/LV ratio was 1.48 (± 0.14) at baseline and 0.85 (± 0.14) at 48 hours with a reduction of 43%. The 2 high-risk patients died: one 1 month after the procedure, due to the effects of cerebral haemorrhage, the other one after 10 days due to respiratory complications. The mean FU of 17 patients was 228 days (± 193);during the FU there was a recurrence of PE (6%) after the discontinuation of anticoagulant therapy;there were no haemorrhages. RV dysfunction persisted in one patient (6%) with CTEPH who subsequently underwent pulmonary endarterectomy. Conclusion: PDTA and teamwork helped to improve the therapeutic decision making in patients with PE at a high and intermediate-high risk, despite the difficulties due to the SARS-COV-2 pandemic. Our experience was found to be in line with what has been published on the efficacy and safety of CT. (Figure Presented).